Bionano Genomics Announces Extensive Lineup of Content to be Presented at the Annual Meeting of the Association for Molecular Pathology Featuring Optical Genome Mapping Across a Broad Range of Clinical Research Applications
Bionano’s corporate workshop on
The innovation spotlight will feature presentations from Dr.
The table below outlines each presentation together with the program number for ease of location during the event.
OGM Application Area | Presentation / Poster Title | Affiliation |
Genetics | G22. Comprehensive Evaluation and Validation of Amniocytes Using Optical Genome Mapping: From Sample Preparation to Reporting | |
Hematopathology | H02. Clinical Validation of Optical Genome Mapping to |
|
H13. Comprehensive Detection of Structural Somatic Mutation in Hematological Cancers by Optical Genome Mapping | ||
H15. Clinical Utility of Optical Genome Mapping in Cytogenetic Analysis of Hematologic Malignancies | ||
Informatics | I12. Detecting Absence of Heterozygosity Using High-Resolution Optical Genome Mapping | |
Solid Tumors | ST74. Optical Genome Mapping for the Chromosomal Characterization of Solid Tumors | |
Technical Topics | TT24. Optical Genome Mapping: Optimizing Sample Types for Prenatal Testing, Constitutional Disorders, Hematological Malignancies, and Solid Tumor Profiling | |
Workshop | Topic | Date and Time |
Combining Optical Genome Mapping (OGM) with Next-Generation Sequencing (NGS) Data to Provide the Most Comprehensive Genome Analysis for Oncology Applications |
“We are thrilled to see the broad range of presentations featuring OGM at AMP this year, including coverage of the combination of OGM with NGS data to provide the most comprehensive picture of the genome,” stated
For more details and to register for this online event please go to: https://amp21.amp.org/
About
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the posters and presentations regarding OGM to be presented at the AMP conference; and the effectiveness and utility of OGM, including in combination with NGS and in comparison to traditional standard of care methods. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the accuracy of customer posters and presentations to be presented; observations from studies covered by the posters and presentations may not be replicated; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the
CONTACTS
Company Contact:
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
+1 (858) 366-3243
amy@juniper-point.com
Media Relations:
Seismic
+1 (503) 799-7520
michael@teamseismic.com
Source: Bionano Genomics